ESC Premium Access

Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure- Contra.

Congress Session

About the speaker

Professor John Cleland

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
56 presentations
6 followers

5 more presentations in this session

Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure - Pro.

Speaker: Associate Professor D. Sim (Singapore, SG)

Thumbnail

Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure concluding discussion.

Thumbnail

PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Pro.

Speaker: Associate Professor M. Marwan (Erlangen, DE)

Thumbnail

PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Contra

Speaker: Associate Professor K. Sin (Singapore, SG)

Thumbnail

PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Concluding discussion.

Thumbnail

Access the full session

Controversies in 2019

Speakers: Professor J. Cleland, Associate Professor D. Sim, Associate Professor M. Marwan, Associate Professor K. Sin
Thumbnail

About the event

Image

ESC Asia with APSC & AFC

8 November - 10 November 2019

Sessions Presentations

Related content

ESC Premium Access

SGLT-2 inhibition in acute heart failure.

3 December 2021

Open Access

CRT, conduction system and alternative site pacing.

29 August 2021

ESC Premium Access

SGLT2 Inhibitors in heart failure.

29 August 2021

This platform is supported by

logo Novo Nordisk